ZIMMER BIOMET HOLDINGS, INC.

Zimmer Biomet (ZBH) will announce its Q1 2025 financial results on May 5th [2]. While long-term growth potential exists due to the expanding ROSA Robotics portfolio and increased procedure volumes [3], [4], concerns remain regarding stagnant revenue and EPS growth, along with below-average ROIC [1], [5]. Rising costs due to staffing shortages and supply chain disruptions also pose challenges [4]. Despite these challenges, the company received CE Mark certification for its RibFix system, expanding its market reach [7], and has shown improved return on capital employed [6]. The overall sentiment towards ZBH remains cautiously optimistic, pending Q1 results.